Are circulating endothelial cells the next target for transcriptome-level pathway analysis in ARDS?

Area of Science:

• Pulmonary Medicine
• Critical Care Medicine
• Translational Research

Background:

• Acute respiratory distress syndrome (ARDS) research has been hampered by patient heterogeneity, leading to a lack of effective mortality-improving pharmacological interventions despite extensive investigation.
• Current soluble biomarkers aid in clinical trial recruitment but lack organ specificity and mechanistic insights into ARDS pathophysiology.
• Advancing ARDS research requires refined definitions of patient subgroups that exhibit more uniform responses to therapeutic interventions.

Discussion:

• Circulating endothelial cells (CECs) shed from damaged vasculature serve as indicators of site-specific inflammatory injury.
• CEC quantification has shown associations with disease severity across various conditions, including myocardial infarction, vasculitides, cancer, and ARDS.
• Analyzing CECs offers a promising avenue to elucidate the specific cellular contributions to disease mechanisms and identify factors driving CEC shedding in ARDS.

Key Insights:

• The transcriptome of circulating endothelial cells (CECs) presents a novel approach to dissecting ARDS heterogeneity.
• CEC analysis can provide organ-specific information and mechanistic insights currently lacking in plasma-soluble biomarker studies.
• Single-cell RNA transcriptomics of CECs holds potential for uncovering novel signals contributing to ARDS pathophysiology.

Outlook:

• Future research should focus on leveraging CEC transcriptomics to identify ARDS subgroups with distinct biological mechanisms and therapeutic responses.
• Developing targeted therapies based on CEC-derived insights could improve outcomes for patients with ARDS.
• This approach may pave the way for personalized medicine strategies in critical care settings for ARDS management.